Tech Company Financing Transactions

Gamida Cell Funding Round

Shavit Capital, Israel Biotech Fund and Israel Healthcare Ventures joined a $40 million venture round for Gamida Cell. The funding round closed on 6/20/2017.

Transaction Overview

Company Name
Gamida Cell
Announced On
6/20/2017
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Undisclosed
Investors

Shavit Capital (Lead Investor) (Gary Leibler)

Israel Biotech Fund

Israel Healthcare Ventures

Novartis BioVenture Fund

VMS Investment Group (Andrew Ng)

Proceeds Purpose
With this financing, we are well-positioned to complete the Phase 3 clinical trial of NiCord with the goal of bringing this lead product candidate to market and filling an important unmet need in bone marrow transplantation for blood cancer patients who cannot rapidly find a fully matched donor.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
673 Boylston St. 4th Floor
Boston, MA 02116
USA
Phone
617-892-9080
Website
www.gamida-cell.com
Email Address
[email protected]
Overview
Gamida Cell is a cell and immune therapy visionary. The company's world-class scientists have developed a broad platform technology to expand functional cells in culture to create unprecedented, life-saving cures for blood cancers such as leukemia and lymphoma and rare genetic diseases such as sickle cell disease.
Profile
Gamida Cell LinkedIn Company Profile
Social Media
Gamida Cell Company Twitter Account
Company News
Gamida Cell News
Facebook
Gamida Cell on Facebook
YouTube
Gamida Cell on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Julian Adams
  Julian Adams LinkedIn Profile  Julian Adams Twitter Account  Julian Adams News  Julian Adams on Facebook
Chief Financial Officer
Shai Lankry
  Shai Lankry LinkedIn Profile  Shai Lankry Twitter Account  Shai Lankry News  Shai Lankry on Facebook
Chief Medical Officer
Ronit Simantov
  Ronit Simantov LinkedIn Profile  Ronit Simantov Twitter Account  Ronit Simantov News  Ronit Simantov on Facebook
Chief Operating Officer
Tzvi Palash
  Tzvi Palash LinkedIn Profile  Tzvi Palash Twitter Account  Tzvi Palash News  Tzvi Palash on Facebook
Chief Scientific Officer
Tony Peled
  Tony Peled LinkedIn Profile  Tony Peled Twitter Account  Tony Peled News  Tony Peled on Facebook
VP - Bus. Development
Josh Hamermesh
  Josh Hamermesh LinkedIn Profile  Josh Hamermesh Twitter Account  Josh Hamermesh News  Josh Hamermesh on Facebook
VP - Bus. Development
Thomas Klima
  Thomas Klima LinkedIn Profile  Thomas Klima Twitter Account  Thomas Klima News  Thomas Klima on Facebook

 

 

Browse more venture capital transactions:

Prev: 6/20/2017: Modacruz venture capital transaction
Next: 6/20/2017: Augury venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.